Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 10 mg/ml - oral liquid, powder for - excipient ingredients: sucrose; citric acid; sodium citrate dihydrate; sodium benzoate; xanthan gum; colloidal anhydrous silica; titanium dioxide; flavour - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therapy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks (see adverse reactions). diflucan iv is indicated for the same conditions in adults and children but should be used only when diflucan cannot be administered orally.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - oral liquid, solution - excipient ingredients: acesulfame potassium; propyl hydroxybenzoate; purified water; maltitol solution; glycerol; sodium citrate dihydrate; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; flavour - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - dibasic sodium phosphate, quantity: 4.3 g; monobasic sodium phosphate, quantity: 18.8 g - oral liquid - excipient ingredients: glycerol; saccharin sodium; sodium benzoate; purified water; flavour - for use as part of a bowel cleansing regimen in preparing adult patients for colon surgery or for preparing the colon for x-ray or endoscopic examination.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 23.4 mg/ml (equivalent: abacavir, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); sorbitol solution (70 per cent) (crystallising); propylene glycol; sodium citrate dihydrate; citric acid; methyl hydroxybenzoate; propyl hydroxybenzoate; saccharin sodium; hydrochloric acid; sodium hydroxide; purified water; flavour - ziagen (abacavir) is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and children (see clinical trials). this indication is based on surrogate endpoints in studies up to 48 weeks in duration.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 6 mg/ml; fexofenadine hydrochloride 6 mg/ml - oral suspension - 6 mg/ml - active: fexofenadine hydrochloride 6 mg/ml excipient: butyl hydroxybenzoate dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer propyl hydroxybenzoate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol active: fexofenadine hydrochloride 6 mg/ml excipient: dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer potassium sorbate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin ethyl succinate -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin ethyl succinate -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

epigenhealth pty ltd - pinus pinaster, quantity: 5.78 mg/ml (equivalent: pinus pinaster, qty 5.78 g/ml; equivalent: procyanidins (of pinus pinaster), qty 3.87 mg/ml) - oral liquid - excipient ingredients: sodium benzoate; purified water; potassium sorbate; glycerol; steviol glycosides; acetic acid; sodium chloride; xanthan gum; flavour - antioxidant/reduce free radicals formed in the body ; helps enhance/promote general health and wellbeing